{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:37Z","timestamp":1777934377447,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study was to test the feasibility and the usefulness of an intensive safety monitoring program to identify adverse drug reactions for medicines under additional monitoring that are used to treat cancer patients within a Portuguese oncology hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This pilot intensive safety monitoring program was a three-month prospective, observational study. Patients undergoing treatment with one of the following medicines were included: nivolumab, olaparib, palbociclib, pembrolizumab, pertuzumab, ramucirumab, ribociclib, trastuzumab emtansine, or trifluridine\/tipiracil. Potential eligible patients were identified by pharmacists based on prescription data. Clinicians used proper paper-based reporting forms to record adverse drug reactions. Clinical secretariats sent those reports through an electronic platform to the pharmacovigilance department for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-five patients were on treatment with selected medicines. Of those, 33 (44%) experienced adverse drug reactions: 23 (69.7%) cases were serious and 5 (15.2%) unexpected. Considering the number of patients exposed to each medicine and the number of patients experiencing adverse drug reactions, trifluridine\/tipiracil (72.7%; 8\/11) was associated with the highest rate of toxicity, followed by olaparib (66.7%; 2\/3), trastuzumab emtansine (50.0%; 3\/6), pertuzumab (47.8%; 11\/23), pembrolizumab (45.5%; 5\/11), palbociclib (25.0%; 1\/4), and nivolumab (18.8%; 3\/16). A total of 59 adverse drug reactions were identified (i.e. 1.8 adverse drug reactions\/patient), mainly gastrointestinal disorders ( n\u2009=\u200915; 25.4%), and blood and lymphatic system disorders ( n\u2009=\u200914; 23.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This intensive safety monitoring program was feasible and allowed identifying serious and unexpected adverse drug reactions, adding value to pharmacovigilance and therefore contributing to improve patient safety. Further research is needed to confirm the findings of this pilot study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219849277","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T02:23:50Z","timestamp":1558578230000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8717","authenticated-orcid":false,"given":"Diogo","family":"Mendes","sequence":"first","affiliation":[{"name":"DruSER.Net \u2013 Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra Regional Pharmacovigilance Unit (UFC), Coimbra, Portugal"}]},{"given":"Gra\u00e7a","family":"Rigueiro","sequence":"additional","affiliation":[{"name":"DruSER.Net \u2013 Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"IPO-C \u2013 Instituto Portugu\u00eas Oncologia de Coimbra Francisco Gentil, E. P. E., Coimbra, Portugal"}]},{"given":"Rui S","family":"Silva","sequence":"additional","affiliation":[{"name":"DruSER.Net \u2013 Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"IPO-C \u2013 Instituto Portugu\u00eas Oncologia de Coimbra Francisco Gentil, E. P. E., Coimbra, Portugal"}]},{"given":"Ana","family":"Penedones","sequence":"additional","affiliation":[{"name":"DruSER.Net \u2013 Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra Regional Pharmacovigilance Unit (UFC), Coimbra, Portugal"},{"name":"Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, Coimbra, Portugal"}]},{"given":"Carlos","family":"Alves","sequence":"additional","affiliation":[{"name":"DruSER.Net \u2013 Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra Regional Pharmacovigilance Unit (UFC), Coimbra, Portugal"},{"name":"Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, Coimbra, Portugal"}]},{"given":"Gabriela","family":"Sousa","sequence":"additional","affiliation":[{"name":"DruSER.Net \u2013 Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"IPO-C \u2013 Instituto Portugu\u00eas Oncologia de Coimbra Francisco Gentil, E. P. E., Coimbra, Portugal"}]},{"given":"Francisco","family":"Batel-Marques","sequence":"additional","affiliation":[{"name":"DruSER.Net \u2013 Drug Safety and Effectiveness Research Network, Coimbra, Portugal"},{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra Regional Pharmacovigilance Unit (UFC), Coimbra, Portugal"},{"name":"Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, Coimbra, Portugal"}]}],"member":"179","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"bibr1-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184360"},{"key":"bibr2-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0380-2"},{"key":"bibr3-1078155219849277","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.10.863"},{"key":"bibr4-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"bibr5-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1217989"},{"key":"bibr6-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2256-9"},{"key":"bibr7-1078155219849277","doi-asserted-by":"publisher","DOI":"10.2165\/11593830-000000000-00000"},{"key":"bibr8-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0260-x"},{"key":"bibr9-1078155219849277","doi-asserted-by":"publisher","DOI":"10.2174\/157488606776930544"},{"key":"bibr10-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.629184"},{"key":"bibr11-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0653-5"},{"key":"bibr12-1078155219849277","doi-asserted-by":"publisher","DOI":"10.2165\/11586620-000000000-00000"},{"key":"bibr13-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1052-1"},{"key":"bibr14-1078155219849277","unstructured":"Instituto Portugu\u00eas de Oncologia de Oncologia Francisco Gentil E.P.E. Relat\u00f3rios Anuais de Acesso a Cuidados de Sa\u00fade, https:\/\/ipocoimbra.com\/relatorios-anuais-de-acesso-a-cuidados-de-saude\/ (accessed 19 November 2018)."},{"key":"bibr15-1078155219849277","unstructured":"European Medicines Agency. List of medicines under additional monitoring | European Medicines Agency, www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/medicines-under-additional-monitoring\/list-medicines-under-additional-monitoring (accessed 10 April 2019)."},{"key":"bibr16-1078155219849277","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0, https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2017, 30 November 2018)."},{"key":"bibr17-1078155219849277","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) \u2013 annex I \u2013 definitions (Rev. 4), www.ema.europa.eu\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf (2017, accessed 1 May 2019)."},{"key":"bibr18-1078155219849277","unstructured":"EMA. Guideline on good pharmacovigilance practices (GVP): annex I \u2013 definitions (Rev 4) www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/05\/WC500143294.pdf (2017, accessed 1 May 2019)."},{"key":"bibr19-1078155219849277","unstructured":"MedDRA. Medical Dictionary for Regulatory Activities website. Welcome to MedDRA, \/www.meddra.org\/ (accessed 9 November 2018)."},{"key":"bibr20-1078155219849277","author":"Batel-Marques F","journal-title":"J Patient Saf"},{"key":"bibr21-1078155219849277","unstructured":"European Medicines Agency. EudraVigilance system overview | Important medical event list | European Medicines Agency, www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/eudravigilance-system-overview (accessed 10 April 2019)."},{"key":"bibr22-1078155219849277","unstructured":"European Medicines Agency. Signal management | Designated medical events | European Medicines Agency, www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management (accessed 10 April 2019)."},{"key":"bibr23-1078155219849277","unstructured":"European Medicines Agency. Medicines under additional monitoring | European Medicines Agency, www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/medicines-under-additional-monitoring (accessed 10 April 2019)."},{"key":"bibr24-1078155219849277","first-page":"95","volume":"6","author":"Tenti E","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"bibr25-1078155219849277","doi-asserted-by":"crossref","unstructured":"Beretta F, Zenoni D and Bonzi D. 5PSQ-109\u2009Active pharmacovigilance in oncology: pharmacological contribution to improve reports. In: Section 5: Patient safety and quality assurance [Internet]. British Medical Journal Publishing Group; 2018, p. A215.1-A215, http:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2018-eahpconf.462 (accessed 18 October 2018).","DOI":"10.1136\/ejhpharm-2018-eahpconf.462"},{"key":"bibr26-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0665-1"},{"key":"bibr27-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0706-9"},{"key":"bibr28-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx187"},{"key":"bibr29-1078155219849277","unstructured":"EMA. Post-authorisation safety studies (PASS) | European Medicines Agency [Internet]. EMA, www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/post-authorisation-safety-studies-pass (accessed 25 October 2018)."},{"key":"bibr30-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.77"},{"key":"bibr31-1078155219849277","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw281"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219849277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219849277","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219849277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:10Z","timestamp":1777688470000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219849277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1177\/1078155219849277"],"URL":"https:\/\/doi.org\/10.1177\/1078155219849277","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]}}}